Peter Goodfellow


Chair of the Board

Peter Goodfellow is a Senior Science Advisor for Abingworth. Peter was previously the Balfour Professor of Genetics at the University of Cambridge before working for SmithKline Beecham (later GSK) as Head of Research. He has founded several biotechnology companies and has sat on the Boards of Prosensa, deCode, , GenSight Biologics, and various medical charities and is also currently Chair of GammaDelta Therapeutics.

Peter holds doctorates from the Universities of Oxford and Bristol. He is also a Fellow of the European Molecular Biology Organisation (EMBO), the Academy of Medical Sciences, and the Royal Society.

 Natalie Mount


Chief Executive Officer

Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles. Natalie was part of the founding management team at GammaDelta Therapeutics where she served as Chief Scientific Officer from its establishment until 2019. Previously she was part of the founding management team at the Cell and Gene Therapy Catapult as Chief Clinical Officer. Her experience also includes 16 years at Pfizer Research and Development working on different modalities across a range of therapeutic areas. Natalie has also held Independent Director positions on the Boards of biotech companies, including GenSight Biologics and Rinri Therapeutics.

Natalie holds a first class degree in Natural Sciences from University of Cambridge and a PhD from University College, London.

Tim Haines


Tim Haines is Chairman and Managing Partner at Abingworth, and has more than 30 years of international management experience in the life sciences industry at both public and private companies. During his time at Abingworth, Tim has taken Chairman and Board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN, PixiumVision, PowderMed, Sientra, and Stanmore.

Before joining Abingworth in 2005, he was the Chief Executive Officer of the Abingworth portfolio company, Astex Therapeutics. At Astex Tim was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, he was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope. Prior to this, he held a number of other senior management positions in the US and Europe, including as Chief Executive Officer of Thackray, and as General Manager of Baxter UK.

Tim has a BSc from Exeter University and an MBA from INSEAD.



Chris is Vice President and Head of Oncology and Cell Therapy Precision & Translational Medicine in the Oncology and Cell Therapy Therapeutic Area Unit at Takeda Pharmaceutical Co in Cambridge MA. Chris has worked in Research & Development in pharma for 20+ years across multiple therapeutic areas (Oncology, Respiratory, Autoimmunity and Infectious Diseases). She joined Takeda in 2020 and was previously at Johnson & Johnson, MedImmune/AstraZeneca and Bristol Myers Squibb. Chris has a passion for using Translational Medicine to enhance drug development decisions and has contributed to the development, approval, and/or post-marketing support of Opdivo®, Yervoy®, Sprycel®, Empliciti® and Orencia® at Bristol Myers Squibb, and FASENRA® at AstraZeneca, and 20+ programs in various stages of clinical development. Chris earned her PhD in Immunology and Infectious Diseases from Virginia Tech and completed a Postdoctoral Fellowship in Immunology and Microbiology at the University of Texas Southwestern Medical Center in Dallas TX.

Loic Vincent


Victor (Yoshihide Ishii) is Partner at Takeda Ventures, based in Cambridge MA. His recent investments and directorships include Code Biotherapeutics, Shattuck Labs (NAS: STTK), and ARTham therapeutics. His role extends into business development activities where he serves on core teams problem solving for Immune oncology, cell therapy, and non-viral gene therapy. In addition, Victor directs a biopharma consortia that coalesces to develop the biotech ecosystem in Japan. Prior to Takeda, Victor was a private equity investor in Japan with track record of launching funds, private equity spin-outs, and cross-border (China) deals.

Victor earned his MD at Jefferson Medical College, and MBA at Harvard Business School. His early career is noteworthy for military service in the US Navy/Marine Corps with combat deployments to Iraq and Afghanistan, and humanitarian service in Bangladesh.

Craig Taylor


John Shields is an independent director who has extensive operational and investment experience in the biotechnology sector. He serves on a number of biotechnology company boards and company science advisory boards. In addition, he is currently a member of the Sanger Institute Translation Committee, the Crick Institute Translation Advisory Group, the Cancer Research UK CoLC SAB, the Biomedical Catalyst Major Awards Committee and the MRC’s Translational Research Group.

Previously John was an employee of Abingworth LLP, the life-sciences focused venture capital group, and has also worked in the pharma and biotech industry, initially at Glaxo and then as SVP Research for Cantab Pharmaceuticals. John has a PhD in Immunology from the University of Glasgow.

Talk to US

This form collects your name and email to enable us to contact you regarding your enquiry. For further information on how we protect and manage your submitted data view our privacy policy.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.